Radiation therapy before stem cell transplant for high-risk blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndrome with certain high-risk features (like not responding to treatment or having specific genetic changes).
- You need a donor whose tissue type is either fully matched or partly mismatched.
- Your heart, lungs, kidneys, and liver must be working well enough for this intense treatment.
- You cannot have received radiation to more than 20% of your bone marrow in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy called automated total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant. It's designed to treat blood cancers like leukemia and myelodysplastic syndrome by destroying cancer cells and preparing the body to accept donor stem cells.
This trial tests a stronger chemotherapy and radiation regimen before a donor stem cell transplant for people with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to eliminate any remaining cancer cells and improve transplant success.
This trial tests a conditioning regimen (total marrow and lymphoid irradiation, fludarabine, and melphalan) before a donor stem cell transplant for people with high-risk myelodysplastic syndrome or acute myeloid leukemia. It aims to reduce side effects while still controlling the disease.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 2 study tests a more precise type of whole bone-marrow radiation before a stem cell transplant. It may help patients with certain high-risk blood cancers by preparing the body for transplant more safely and effectively.
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.